{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:30:56Z","timestamp":1782786656718,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.atherosclerosis.2021.11.016","type":"journal-article","created":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T10:46:34Z","timestamp":1638009994000},"page":"7-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Galectin-3 is linked to peripheral artery disease severity, and urinary excretion is associated with long-term mortality"],"prefix":"10.1016","volume":"341","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6176-6996","authenticated-orcid":false,"given":"Martin","family":"Ursli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Zierfuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Grigassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerfried","family":"Pesau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Koppensteiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9587-1727","authenticated-orcid":false,"given":"Gerit-Holger","family":"Schernthaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9704-1452","authenticated-orcid":false,"given":"Clemens","family":"H\u00f6baus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.atherosclerosis.2021.11.016_bib1","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1161\/CIRCULATIONAHA.109.865600","article-title":"Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease","volume":"120","author":"Diehm","year":"2009","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.atherosclerosis.2021.11.016_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejvs.2006.09.024","article-title":"Inter-society consensus for the management of peripheral arterial disease (TASC II)","volume":"33","author":"Norgren","year":"2007","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2021.11.016_bib3","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1161\/ATVBAHA.120.314824","article-title":"Fibrosis and inflammatory markers and long-term risk of peripheral artery disease: the ARIC study","volume":"40","author":"Ding","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2021.11.016_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11897-010-0004-x","article-title":"Galectin-3 in cardiac remodeling and heart failure","volume":"7","author":"de Boer","year":"2010","journal-title":"Curr. Heart Fail. Rep."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2021.11.016_bib5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2353\/ajpath.2008.070348","article-title":"Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice","volume":"172","author":"Nachtigal","year":"2008","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2021.11.016_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijcard.2014.09.011","article-title":"Renal function largely influences Galectin-3 prognostic value in heart failure","volume":"177","author":"Zamora","year":"2014","journal-title":"Int. J. Cardiol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2021.11.016_bib7","first-page":"1016","article-title":"Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages","volume":"147","author":"Liu","year":"1995","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2021.11.016_bib8","first-page":"1199","article-title":"Galectin-3 expression in human atherosclerotic lesions","volume":"152","author":"Nachtigal","year":"1998","journal-title":"Am. J. Pathol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2021.11.016_bib9","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/glycob\/cwt006","article-title":"Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice","volume":"23","author":"MacKinnon","year":"2013","journal-title":"Glycobiology"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2021.11.016_bib10","article-title":"Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis","volume":"3","author":"Madrigal-Matute","year":"2014","journal-title":"J. Am. Assoc."},{"key":"10.1016\/j.atherosclerosis.2021.11.016_bib11","first-page":"1","article-title":"Galectin-3 is not predictive of cardiovascular events in patients with peripheral artery disease","author":"Blinc","year":"2021","journal-title":"Vasa"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2021.11.016_bib12","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1161\/ATVBAHA.114.304964","article-title":"Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease","volume":"35","author":"Maiolino","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2021.11.016_bib13","article-title":"Chronic kidney disease and outcomes of lower extremity revascularization for peripheral artery disease","author":"Smilowitz","year":"2019","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2021.11.016_bib14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.kint.2017.06.028","article-title":"Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease","volume":"93","author":"Rebholz","year":"2018","journal-title":"Kidney Int."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2021.11.016_bib15","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1681\/ASN.2012090909","article-title":"Elevated galectin-3 precedes the development of CKD","volume":"24","author":"O'Seaghdha","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2021.11.016_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00432-008-0481-4","article-title":"Galectin-3 in urine of cancer patients: stage and tissue specificity","volume":"135","author":"Balasubramanian","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2021.11.016_bib17","article-title":"Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis","volume":"3","author":"Meijers","year":"2014","journal-title":"J. Am. Assoc."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2021.11.016_bib18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/07853890.2016.1241428","article-title":"Center-based patient care enhances survival of elderly patients suffering from peripheral arterial disease","volume":"49","author":"Hobaus","year":"2017","journal-title":"Ann. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.016_bib19","author":"World Medical Association"},{"key":"10.1016\/j.atherosclerosis.2021.11.016_bib20","author":"European Parliament C","year":"2001"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2021.11.016_bib21","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2021.11.016_bib22","first-page":"63","article-title":"Chapter 2: definition, identification, and prediction of CKD progression","volume":"3","year":"2011","journal-title":"Kidney Int. Suppl."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2021.11.016_bib23","doi-asserted-by":"crossref","first-page":"11061","DOI":"10.1038\/s41598-021-90395-0","article-title":"Urinary fatty acid binding protein 3 (uFABP3) is a potential biomarker for peripheral arterial disease","volume":"11","author":"Zamzam","year":"2021","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2021.11.016_bib24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/1358863X16644059","article-title":"Differences in galectin-3, a biomarker of fibrosis, between participants with peripheral artery disease and participants with normal ankle-brachial index","volume":"21","author":"Casanegra","year":"2016","journal-title":"Vasc. Med."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2021.11.016_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18050973","article-title":"Galectin-3 in peripheral artery disease. Relationships with markers of oxidative stress and inflammation","volume":"18","author":"Fort-Gallifa","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.atherosclerosis.2021.11.016_bib26","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.3760\/cmaj.issn.0366-6999.20130217","article-title":"Serum galectin-3: a risk factor for vascular complications in type 2 diabetes mellitus","volume":"126","author":"Jin","year":"2013","journal-title":"Chin. Med. J."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2021.11.016_bib27","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1007\/s00125-018-4552-z","article-title":"Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus","volume":"61","author":"Tan","year":"2018","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2021.11.016_bib28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ekir.2018.09.013","article-title":"Soluble ST2 and galectin-3 and progression of CKD","volume":"4","author":"Alam","year":"2019","journal-title":"Kidney Int. Rep."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915021014441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915021014441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:26:48Z","timestamp":1762187208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915021014441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":28,"alternative-id":["S0021915021014441"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.11.016","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Galectin-3 is linked to peripheral artery disease severity, and urinary excretion is associated with long-term mortality","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}